High-dose chemotherapy with stem cell rescue to treat stage III homologous deficient breast cancer: factors influencing clinical implementation.

Joost G E VerbeekVincent M T de JongHanna M WijnjaAgnes JagerSabine C LinnValesca P RetèlWim H van Harten

Published in: BMC cancer (2023)

In anticipation of a positive reimbursement decision, we recommend to take the highlighted implementation factors into consideration. This might expedite and guide high-quality equitable access to HDCT for patients with stage III, HER2-negative, HRD breast cancer in the Netherlands.

Keyphrases

high dose
stem cells
primary care
healthcare
quality improvement
low dose
dna repair
squamous cell carcinoma
locally advanced
decision making
oxidative stress
radiation therapy
young adults
mesenchymal stem cells
cell therapy
rectal cancer